Plasma cell myeloma
Not recruitingStudy on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity
Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity
- Disease:Plasma cell myeloma
- Substances:BortezomibCarfilzomib+4
Norway- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Oslo University Hospital HF












